Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Glucocorticoid Clear all
Terminated Phase 1Phase 2 Interventional Results available

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

NCT02906670
View directory record Official record
Conditions
Oncology
Interventions
Sym013
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 7, 2026, 10:35 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

NCT00801138
View directory record Official record
Conditions
Anesthesia, Local, Shoulder Surgery
Interventions
saline, Dexamethasone, ropivacaine, Bupivacaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 7, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease

NCT01143493
View directory record Official record
Conditions
Glucose Homeostasis, Protein Metabolism, Lipid Metabolism, Respiratory Function, Connective Tissue Metabolism
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 7, 2026, 10:35 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 7, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid Effects on Cellular Cytokine Release

NCT00001415
View directory record Official record
Conditions
Depressive Disorder, Fatigue Syndrome, Chronic, Fibromyalgia, Healthy, Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 10:35 PM EDT
Completed No phase listed Observational Results available

Pilot Study Assessing Oxidative Stress in Children

NCT01052207
View directory record Official record
Conditions
Adrenal Insufficiency, Critical Illness
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

NCT01488279
View directory record Official record
Conditions
Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions
Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 7, 2026, 10:35 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Intervention to Increase Screening for Glucocorticoid Induced Diabetes

NCT01743963
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Decision support, Usual Care
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 7, 2026, 10:35 PM EDT
Recruiting Phase 3 Interventional

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196
View directory record Official record
Conditions
Immunoglobulin G4 Related Disease
Interventions
Rilzabrutinib, Placebo, Glucocorticoid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Fontana, California • San Jose, California • Tustin, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

NCT01808040
View directory record Official record
Conditions
Post Menopausal, Hormone Receptor Positive Breast Cancer
Interventions
TAK700
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

NCT01940094
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
5 mg Prednisone, 0 mg Prednisone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Terminated Phase 3 Interventional

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

NCT00005777
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
Procedure · Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
5 Minutes to 10 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 7, 2026, 10:35 PM EDT
Enrolling by invitation No phase listed Observational

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

NCT06270719
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Delandistrogene Moxeparvovec, Standard of Care
Genetic · Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional

Study of ORIC-101 in Combination With Anticancer Therapy

NCT03928314
View directory record Official record
Conditions
Solid Tumor
Interventions
ORIC-101, Nab-paclitaxel
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease

NCT03983837
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Neocate Splash
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

NCT04254627
View directory record Official record
Conditions
Gulf War Illness
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Davie, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 7, 2026, 10:35 PM EDT
Withdrawn Phase 3 Interventional

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

NCT03532022
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, Standard Care
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 7, 2026, 10:35 PM EDT
Completed No phase listed Observational

Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism

NCT00004354
View directory record Official record
Conditions
Hyperaldosteronism
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 10:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

NCT03277352
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876, Epacadostat, Pembrolizumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 7, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cortisol Control of Human Inflammatory Responses to Endotoxin

NCT00396344
View directory record Official record
Conditions
Sepsis
Interventions
Çontrol, Hydrocortisone
Other · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Sep 7, 2026, 10:35 PM EDT
Withdrawn Phase 2 Interventional

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

NCT06348147
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 7, 2026, 10:35 PM EDT